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Executive Summary
Traditionally, resource utilization and value considerations
have been explicitly excluded from practice guidelines and
performance measures formulations, although they often
are implicitly considered. This document challenges this
historical policy. With accelerating healthcare costs and the
desire to achieve the best value (health beneﬁt for every
dollar spent), there is growing recognition of the need for
more explicit and transparent assessment of the value of
health care. Thus, from a societal policy perspective, a
critical healthcare goal should be to achieve the best pos-
sible health outcomes with ﬁnite healthcare resources.
Consideration of cost/resource utilization as an outcome
presents special challenges. Frequently, the scientiﬁc evi-
dence base is inadequate to accurately assess cost-beneﬁt.
Also, costs may vary widely by practice setting, locality, and
nationality, and over time. Moreover, individuals bear the
burden of adverse health outcomes, yet costs typically are
shared by society (e.g., by families, employers, government,
premium payers, fellow employees, taxpayers). Finally,
attitudes differ among stakeholders about the extent to
which cost should inﬂuence treatment decisions for indi-
vidual patients and who should bear these costs. Con-
sequently, resource utilization debates often become highly
politicized, and signiﬁcant conﬂicts of interest among
individuals impaneled to formulate resource-based guide-
lines may be difﬁcult to avoid.
A transparent and consistent approach to considering
value is needed when making healthcare decisions. This
must begin with an understanding of key economic con-
cepts, including allocation of resources to produce more
health care of various types, methods for assessing the
monetary value of these resources, and the perspective used
for making this assessment of the value of healthcare
expenditures (i.e., societal perspective, individual patient
costs, hospital costs, and payer costs). Methodological
challenges include limitations in the robustness and quality
of value evidence, regional variations in costs, and outdated
(temporally dynamic) and biased data.
Despite these challenges, the writing committee agreed
that progress has been made in these areas and that the
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resource issues has become acute enough that the time has
come to include cost-effectiveness/value assessments and
recommendations in practice guidelines and performance
measures. The writing committee chose to emphasize the
nomenclatures of “value” and “resource utilization” over
“cost.” Given evidence and resource limitations, the
writing committee also recognized the need to selectively
target guidelines and performance measures for initial
resource use evaluation. A plan for performing a thor-
ough, independent literature search and a consistent
method for assessing the quality and potential for bias
of identiﬁed articles should be prospectively designated.
The evidence base then should be synthesized to provide
an overall value classiﬁcation together with a supporting
level of evidence, which should be reported alongside
but separate from the scientiﬁc class and level/quality
of evidence.
The proposed level of value (LOV) categories, outlined
in Section 5 of this paper, are high value (H), intermediate
value (I), and low value (L), augmented as appropriate
with uncertain value (U) and value not assessed (NA).
For example, high value might be set at <$50,000 and
low value at >$150,000 per quality of life-year added,
indexed to gross domestic product (GDP) or as otherwise
determined by agreed-on societal norms. The value category
(i.e., H, I, L, U) would be supplemented by a level/quality
of evidence paralleling those for scientiﬁc level of evidence
(i.e., A, B, and C) and based on the robustness of
the database supporting the value category. These value
assessments would also inform development of performance
measures. Class I recommendations determined to be of
low value would not be recommended as performance
measures. Because the value of a given care practice will
change if the cost or beneﬁt of the practice changes, timely
review and updates of guidelines will be even more
important when value determinations are included in the
guidelines.
This report stresses that the value category should be
only one of several considerations in medical decision
making and resource allocation. Providers and society may
be willing to pay more for the only effective treatment for
a rare disease (e.g., congenital versus adult cardiac care).
As noted, given differing methodologies, quality of evi-
dence, and temporal and geographic dynamics of resource
and value assessments, the value level of a recommendation
should be given separately and not averaged together with
the level/quality of evidence from clinical trial results as a
single metric. It is anticipated that these will usually be
concordant, but in some cases, discordance may be noted
(e.g., an intervention is shown to provide a small incre-
mental health care beneﬁt but at a high cost in resources).
Deﬁning how medical decision making should be affected
in speciﬁc instances by such discordance between value
and guideline recommendations is controversial, but
highlighting these instances explicitly and transparentlywill further inform appropriate discussion and policy
making.
1. Preface
1.1. Scope
Traditionally, explicit considerations of resource utilization
and value in health care have been excluded from clinical
practice guidelines and performance measures. However,
given accelerating health care costs and the desire to
optimize value for each healthcare dollar spent, there has
been growing recognition of the need for more explicit and
transparent considerations of resource utilization in med-
ical practice. To address this issue, this document sum-
marizes the rapidly evolving healthcare landscape; assesses
the reasons for and against considering resource utilization
and value in recommendations for practice guidelines and
performance measures; reviews relevant, contemporary
economic concepts; and proposes a level of value assess-
ment to complement the traditional Class of Recom-
mendation (COR)/Level of Evidence (LOE) system for
recommendations, seen in Appendix 1. Finally, future
directions and needs are highlighted.
1.2. Structure and Membership of the
Writing Committee
The members of the writing committee included experi-
enced clinicians and specialists in cardiology, health eco-
nomics, and performance measures methodology.
1.3. Disclosure of Relationships With
Industry and Other Entities
The ACC/AHA Task Force on Performance Measures
and the ACC/AHA Task Force on Practice Guidelines
make every effort to avoid actual, potential, or perceived
conﬂicts of interest that may arise as a result of relation-
ships with industry or other entities (RWI). All members
of the writing committee, as well as peer reviewers for this
document, were required to disclose all current relation-
ships and those existing within 12 months before initiation
of this writing effort. It was also required that the writing
committee co-chairs and at least 50% of the writing
committee members have no relevant RWI. Because this is
a methodology document and the writing committee did
not deﬁne performance measures or develop guideline
recommendations, members’ relationships with pharma-
ceutical and device companies were not considered relevant
to the topic of this document. The only relationships that
were considered relevant were relationships with com-
mercial grouper tools, such as episode treatment groupers
that group related services into episodes of care. Cost and
resource information is then generated for these episodes.
Any writing committee member who developed new
RWI during his or her tenure on the writing committee
was required to notify staff in writing. These statements
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of the writing committee. Author and peer reviewer rela-
tionships with industry and other entities relevant to
the document are listed in Appendix 2 (writing committee
members) and Appendix 3 (peer reviewers). Additionally,
to ensure complete transparency, writing committee
members’ comprehensive disclosure information, including
relationships not relevant to the present document, is
available online at http://jaccjacc.cardiosource.com/DataSupp/
TFPM_TFPG_Comprehensive_RWI_Authors_and_Peer_
Reviewers.pdf. Disclosure information for both task forces
is also available online at http://www.cardiosource.org/ACC/
About-ACC/Who-We-Are/Leadership/Guidelines-and-
Documents-Task-Forces.aspx.
The work of the writing committee was supported
exclusively by the American College of Cardiology (ACC)
and the American Heart Association (AHA) without
commercial support. Writing committee members vol-
unteered their time for this effort. Meetings of the writing
committee were conﬁdential and attended only by com-
mittee members and staff from the ACC, AHA, and
American Medical AssociationPhysician Consortium for
Performance Improvement (which provided a liaison to
this writing committee).
2. Introduction
2.1. Background
The ACC and AHA have jointly developed clinical
practice guidelines for nearly 3 decades, based on their
shared belief that the medical profession should play a
major role in the evaluation and synthesis of the evidence
that will guide the care of patients with cardiovascular
disease. Expert analysis of the available data on the risks,
beneﬁts, and alternatives to speciﬁc treatments, procedures,
and management strategies (i.e., medical programs) can
improve the quality of care and patient outcomes. More-
over, clinical practice guidelines serve as the underpinnings
for performance measures used to characterize and improve
the quality of cardiovascular care. Together, the ACC and
AHA have also developed an explicit methodology to
select and create performance measures (1,2).
Although review and analysis of existing evidence has
the potential to favorably affect health care spending by
targeting the use of resources to the most effective thera-
pies, to date, considerations of value and resource use
have been explicitly excluded from formal consideration
in formulating ACC/AHA clinical practice guidelines
and performance measures, although they may have been
implicitly considered. Guideline writing committees are
encouraged to be informed about cost when information is
available, but data on clinical efﬁcacy and outcomes con-
stitute the primary basis for their recommendations.
However, given the challenge of accelerating health care
costs combined with ﬁnite resources, there is an ever-increasing need to be more explicit and transparent about
value, which can be deﬁned as the incremental health
beneﬁts of a therapy or procedure relative to its incremental
net long-term costs. Additionally, the U.S. Food and Drug
Administration does not include cost or value in its
approval process, further necessitating that medical soci-
eties bring this issue forward.
The approach taken by other physician specialty soci-
eties in considering costs in developing clinical guidance
documents has varied. A recent survey reported that
slightly more than half of the largest U.S. physician
societies explicitly consider costs in developing their
guideline documents, although their approach remains
vague (3). The authors concluded by recommending
greater transparency and rigor in the approach to cost
consideration in guideline documents from medical
societies going forward.
Although the ACC/AHA guidelines have not explicitly
addressed the issue of costs in the past, the ACC and
AHA have addressed issues related to resource stewardship
since ACC/AHA guidelines were ﬁrst produced. Indeed,
the ﬁrst guideline (1984) dealt speciﬁcally with the appro-
priate use of pacemakers and was written at the request of
the Health Care Financing Administration (now the
Centers for Medicare & Medicaid Services) because of the
agency’s concern about the rapidly increasing number of
pacemaker implants. In moving toward an explicit con-
sideration of resource utilization and value in the ACC/
AHA clinical guidance documents, the overarching goal of
this document’s writing committee is to facilitate the
achievement of the best possible health within the conﬁnes
of available resources.
2.2. Sustainability of the Healthcare System
For the past 40 years, U.S. spending on health care has
been growing substantially faster than the economy.
From 1997 to 2010, per capita spending doubled from
$4,166, or 13.7% of the GDP, to $8,402, or 17.9% of the
GDP (see Figure) (4). The projected future increase
in Medicare expenditures is a major contributor to the
estimated future federal budget deﬁcit and represents a
nonsustainable trend. At the state level, the annual increase
in total Medicaid expenditures has consistently exceeded
the increase in state tax revenues for 40 years; total state
spending on Medicaid now surpasses kindergarten to
12th-grade education spending by a considerable amount
(5). A less well-recognized future concern for states is the
projected health-beneﬁt costs for retired state employees
and teachers. The growth of healthcare costs as a percentage
of GDP, future Medicare projections, the current Medicaid
burden, and state retiree beneﬁt obligations all contribute
to unsustainable future healthcare costs. This should be a
concern to all healthcare professionals.
Increases in healthcare costs have fueled concerns about
the overuse and misuse of costly procedures and therapies.
Most of the discussion has centered on overuse, because
Figure. National Health Spending 1997–2010
Figure: Whether expressed as a percentage of GDP, as per capita spending, or as total national US health expenditures (shown here), healthcare spending has risen dramatically
from 1997 to 2010.
Source: National health expenditures. National Institute for Health Care Management (6).
National health expenditures as a percent of gross domestic product. Centers for Medicare and Medicaid Services (7).
GDP indicates gross domestic product.
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correction of underuse is also relevant to optimizing
health care and controlling long-term costs. It is estimated
that overuse wastes $210 billion annually (8). Regional
variation in care across the United States is another issue;
for >20 years, the Dartmouth Atlas Project (http://www.
dartmouthatlas.org) has documented signiﬁcant regional
variations in use of medical care without signiﬁcant
differences in health outcomes. The variation in care is
primarily due to regional differences in practice rather
than different rates paid by Medicare, poverty level
(where the poor may be sicker), rates of illness, or patient
acuity (9). The central issue is that more care and higher
spending do not necessarily translate into better quality
of care or outcomes. Indeed, population metrics indicate
that the health of several developed nations exceeds that
of the United States, although their per capita healthcare
expenditures are far less (10).
2.3. Value in Healthcare
Given the escalating costs of health care, variations in
delivery of care, and potential for inappropriate use of
therapies and procedures, many authorities have concluded
that all involved in the healthcare system need to increase
emphasis on value in health care (11). One deﬁnition of
value is that it represents health care that has positive results
(improved patient outcomes, safety, and satisfaction) at a
total cost that is reasonable and affordable. Care is of
high value if it enhances outcomes, safety, and patient
satisfaction at a reasonable cost. Care is of low value if it
contributes little to outcomes, safety, and satisfaction or
incurs an inappropriately high cost. Unfortunately, thecurrent reimbursement fee-for-service system fosters more
procedures and more care, which is not necessarily better
or of higher value. Although the traditional approach
to evidence review for development of the ACC/AHA
guidelines and performance measures has not formally
considered value provided for money spent, the writing
committee believes that it is now imperative to modify this
paradigm and consider value and cost in future guidelines
and performance measures. As payment models evolve, it
will be important that patients continue to have access to
high-value care. The importance of adding cost-effectiveness
information is not just to curb the excesses of the fee-
for-service system but also to guard against the unintended
effects of capitation-based reimbursement.
A simple example illustrates this issue. In the non-
invasive evaluation of patients with chest pain who are
able to exercise and have normal resting electrocardio-
grams, the ACC/AHA guidelines have recommended
treadmill exercise electrocardiographic testing as a ﬁrst
step (12). A recent randomized study compared this
strategy with exercise myocardial perfusion imaging as
the ﬁrst step in evaluating a population of women at
low to intermediate risk (13). Outcomes over 2 years
were not signiﬁcantly different between the 2 groups.
However, costs were far higher in the group evaluated
with initial exercise myocardial perfusion imaging. Thus,
exercise treadmill electrocardiographic testing without
imaging was more cost-effective (greater beneﬁt for cost
expenditure).
Given these considerations, the recommendation to
consider cost and value in the guideline development
process has these goals: 1) to enhance overall value in the
JACC Vol. 63, No. 21, 2014 Anderson et al.
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2309delivery of cardiovascular care and 2) to involve healthcare
professionals in the difﬁcult decisions that must be made to
increase value in the U.S. healthcare system. This need is
emphasized by the unsustainable increase in healthcare
costs, ﬁnite healthcare resources, and the critical role
healthcare professionals play in resource utilization. The
emergence and rapid growth of accountable care organ-
izations is a societal effort in this direction and for which
valid resource and cost-effectiveness information, together
with appropriately aligned incentives for healthcare pro-
fessionals, will be critical. In this context, we refer to
the health and economic beneﬁts of a health promotion
or disease mitigation measure as value and are cognizant
of but eschew such implications as worth, quality, useful-
ness, importance, desirability, reasonableness, and appro-
priateness. Subsequent sections of this document will
outline a proposed methodology to explicitly incorporate
the issue of value into future guidelines and performance
measures.3. Reasons to Consider Resource Utilization
and Value in Recommendations for
Guidelines and Performance Measures
The ACC/AHA guidelines and performance measures are
based on the principle that comprehensive analysis of
clinical data documenting beneﬁts and risks of diagnostic
or therapeutic strategies and procedures can improve the
effectiveness of patient care and optimize patient out-
comes. The conventional premise governing performance
measures and guideline recommendations, however, is that
all healthcare professionals should act in the best interests
of their patients without regard to costs. This premise was
never realistic, because medical recommendations always
have economic consequences for patients and may expose
them to high out-of-pocket costs. It would not be in the
patient’s best interest for the clinician to ignore costs and
recommend treatments that the patient cannot afford (e.g.,
forcing the patient to choose between paying for groceries
or medications). In 2007, a large percentage (62.1%) of
personal bankruptcies in the United States were caused
by medical bills (14). Protecting patients from ﬁnancial
ruin is fundamental to the precept of “do no harm” (15).
Furthermore, even when the costs of medical care are
borne collectively rather than individually, rising health
insurance premiums and taxes that support government-
provided health beneﬁts are paid ultimately by all
consumers (and patients). Decisions by clinicians control
the bulk of these expenditures, and good stewardship is
essential. Consequently, clinical practice guidelines and
performance measures that consider value will enhance the
sensitivity of providers, payers, and patients to the limits
of available healthcare resources and generate the best
possible set of outcomes in that context. An important
challenge in implementation is the lack of training amongmedical professionals with respect to health economics
and knowledge of cost-effectiveness and value of medical
strategies; the growing importance of recognizing the cost
of care highlights the need to integrate training in these
issues into medical schools and training programs.
3.1. Arguments in Favor of Incorporating
Resource and Value Considerations
Economic evaluations, including cost-effectiveness analy-
ses, can help decision makers appreciate the implications
of choices and clarify factors inﬂuencing relative beneﬁts.
In addition to informing clinicians about their responsi-
bility to their patients, economic analyses can guide those
making coverage decisions and inform developers of prac-
tice guidelines to ensure that recommendations yield
the greatest value from available healthcare resources (16).
Currently, algorithms for diagnosis or management of
disease states, including appropriate use of clinical
interventions, typically consider a broad spectrum of
differential diagnoses and patient care approaches, which
essentially assume that resources are unlimited. The
principal consideration is not cost awareness but a
comprehensive, informed, and evidence-based approach
in which incentives are balanced by the need to consume
resources more wisely.
3.2. Limitations, Challenges, and Arguments
Against Incorporating Resource and
Value Considerations
Barriers to acceptance of guideline recommendations
based on value include widespread unwillingness to
acknowledge that resources are limited, distrust of gov-
ernment and other policy decision makers, and lack of
conﬁdence in the science of value determination (cost-
effectiveness) (17). Another limitation is that the value
of care (cost-effectiveness) is not constant; it may vary
over time and from one location to another because of
differences or changes in resource availability, efﬁciency,
and cost structure. Further, cost deﬁned as dollars spent as a
resource measure is confounded by contractual allowances
and other insurance, provider, and payer variables. Hence,
the writing committee favors the concept of cost as true
resource utilization.
Another challenge involves the integration of long-
term costs, such as development of the infrastructure
required to provide an intervention in acute situations
(e.g., in the emergency department or intensive care unit)
into a per-treatment cost through amortization over the
useful life of a given resource. The decision to make the
initial investment entails an array of considerations that
are separatedor at least distantdfrom those regarding
the cost-effectiveness of implementation at the patient
care level. Increasingly, however, as these barriers
are identiﬁed, methods to overcome them have been
developed.
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regarding the role of cost-effectiveness considerations in
healthcare decision making. Even if consensus that such
data should inform decision making were achieved, the
high-quality economic information needed to formulate
recommendations that encompass most spending choices
is limited. Attempts to use cost-effectiveness criteria to
establish spending priorities have been limited and generally
less successful than in some other countries, where initiatives
are largely intended to control overall healthcare expendi-
tures in the face of ﬁxed healthcare budgets (18).
Nevertheless, although data on cost-effectiveness are not
comprehensive, the evidence that is available is informative
and increasing. It is the hope of the writing committee
that this document will encourage routine assessment of
cost-effectiveness in the future, such that, for example,
when a new technology is evaluated in multicenter trials,
the study design will include an analysis of comprehensive
resource utilization and cost-beneﬁt.
The writing committee also recognizes that its focus on
the value of individual procedures and therapies in this
document does not address system changes that may
improve efﬁciency of cardiovascular care, such as expansion
of interdisciplinary cardiac care teams, greater emphasis on
prevention, coverage of the uninsured, and replacing fee-
for-service (including self-referral) with accountable care
(capitated) care reimbursement models.3.3. Special Considerations
Given the many current limitations and controversies in
assessing optimal resource utilization (19), the goal of
incorporating considerations of value into guideline
recommendations should be to provide information rather
than to be prescriptive. Efforts to incorporate value should
focus on interventions associated with high costs or volume.
Published studies of resource use, identiﬁed by using
standard search techniques and reviewed by using general
criteria for quality, should be part of a comprehensive
evidence review (20), noting that the methodology to assess
the quality of economic studies is not as well developed
as that used to judge efﬁcacy in clinical trials.3.4. Summary
The objective of incorporating value into guideline rec-
ommendations is to supplement evidence of safety and
efﬁcacy with information about the resources needed to
achieve health improvements. Although guideline writing
panels may ﬁnd data sufﬁcient to make ﬁrm recom-
mendations based on resource considerations in only a
limited number of circumstances, incorporating value into
recommendations will encourage more thoughtful inves-
tigation and discussion of economic issues going forward
and, when resources are constrained, may prioritize
implementation of services with the greatest value.4. Key Economic Concepts
4.1. Scarcity and Opportunity Costs
Several important concepts underlie the approach that
economists use to examine issues in health care, the most
fundamental of which is the concept of scarcity. Simply
put, societies do not have enough resources to satisfy all
of their citizens’ wants and needs. Therefore, choices, or
more precisely trade-offs, must be made. Introductory
economic courses express this need for trade-offs as “guns
versus butter”: a society that decides to invest more in the
production of weapons (defense) will have fewer resources
to invest in the production of food. The need for trade-
offs, in turn, underlies the economist’s notion of cost as
that which must be sacriﬁced to obtain something else
(“opportunity cost”).
The opportunity cost of medical care is whatever else
we might desire that cannot be produced because of the
decision to produce more health care. In a wealthy society,
such as the United States, it may seem that there are
sufﬁcient resources to do almost anything without any
sacriﬁce. The growing U.S. national debt, driven to a
substantial extent by the cost of government healthcare
programs, however, is a reminder that the notion of
inexhaustible wealth is an illusion and that deferring trade-
offs does not eliminate the need to make them.
4.2. Efﬁciency, Cost-Beneﬁt, and
Cost-Effectiveness
A second critical economic concept is that of efﬁciency.
Given the issue of scarcity and the need for trade-offs,
mainstream economists accept that the objective of eco-
nomic policy is to maximize the well-being (sometimes
referred to as utility) of the members of society collectively.
Economists regard the discipline of economics as a tool to
provide policy makers with the information needed to
make more informed choices in the pursuit of this objec-
tive. Cost-beneﬁt and cost-effectiveness analysis are tools
that quantify the efﬁciency of different policy choices by
relating the incremental costs of producing the new good
or service to its incremental beneﬁts, which can be viewed
as a measure of value (beneﬁt provided for a given cost).
Economists prefer cost-beneﬁt analysis because it
measures the beneﬁts of an intervention or program in
monetary terms and leads to the simple rule that the policy
should be adopted if the beneﬁts (in dollars) exceed the
costs (in dollars). Clinicians and health service researchers,
however, have generally been uncomfortable with meas-
uring health beneﬁts in terms of dollars and therefore
prefer to use cost-effectiveness analysis, in which health
beneﬁts are expressed as improvements in survival or
quality-adjusted survival, which does not require putting a
dollar value on human life.
Cost-effectiveness analysis is best suited to decisions
made in allocating a ﬁxed budget to maximize
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is rarely made, even in single-payer health systems, so
cost-effectiveness in medicine is used as a measure of
clinical value informing policy but is not directly used to
allocate healthcare resources.
4.3. Societal Perspective
Another key principle in the economic evaluation of health
care is that all costs associated with a medical intervention
or program should be counted, regardless of who pays
for them (i.e., a “societal perspective”). This principle
is important because healthcare costs are often divided
among patients, providers, and payers, each of whom may
be more concerned about their share of the cost than the
total cost. Shifting costs from a hospital to a patient or
from an insurer to a provider does not save money; it
merely redistributes it. Thus, all costs should be included,
irrespective of who pays for them.
4.4. Initial and Subsequent Costs
Another important principle of economic evaluation is that
health care decisions may have long-term economic effects,
so the analysis should include both initial and subsequent
costs of a given care program. For example, early discharge
of patients from the hospital may decrease initial costs of
care but might increase total costs if patients are readmitted
more often. The decision to implant a medical device
might incur substantial “downstream” costs for monitoring,
device-related complications, and subsequent device repair
or replacement. An important corollary to this principle is
that the overall net cost of an intervention may be sub-
stantially lower or even “pay for itself” if it prevents future
clinical events. Conversely, an initially low-cost medical
decision can incur substantial overall costs due to the
subsequent need for additional treatments, occurrence of
clinical events, or both. Therefore, the time horizon of an
economic evaluation must be of sufﬁcient duration to
include all costs and health beneﬁts of the medical inter-
vention or program under study. For studies involving
chronic diseases, cost-effectiveness guidelines recommend
a life-long time horizon. This often requires a model to
project or simulate costs and beneﬁts beyond the time
frame of a clinical trial, which can create challenges.
4.5. Patient-Centered Outcomes and
Quality-Adjusted Life-Years
Determining the health beneﬁts of a medical intervention or
program is more difﬁcult (and may bemore inﬂuential on the
results of the analysis) than determining its overall cost.
Incremental health beneﬁts include such things as improve-
ments in symptoms, functional capacity, well-being, and
length of life.One key principle of economic evaluation is that
these clinical consequences should be assessed by using
patient-centered outcomes, such as symptoms or major clin-
ical events, rather than by changes in surrogate markers (e.g.,
cholesterol levels). In the ﬁnal analysis, medical interventionsor programs beneﬁt patients by extending their survival,
improving their quality of life, or both.
The Quality-adjusted life-year (QALY) is the standard
measure of outcomes used in economic evaluation. It
represents years of survival adjusted for quality of life using
a scale of utilities ranging from 0 (equivalent to death) to 1
(perfect health). The utility scale is constructed so that
patients assign equal value to interventions that generate
the same improvement in QALYs, regardless of whether
this is accomplished by lengthening survival or improving
quality of life. Economic evaluation of a medical inter-
vention, service, or program is often expressed using a cost-
effectiveness ratio (i.e., dollars per QALY). An important
advantage of using QALYs to evaluate outcomes is that the
decision maker can compare the relative value of inter-
ventions for different diseases using a common measure.
In practice, it can be difﬁcult to measure QALYs, because
the tools available to assess the quality weights (utilities)
have methodological limitations and may yield different
results. Despite the controversies about the use of QALYs
in economic evaluation, which are outside the scope of
the present discussion, QALYs represent the preferred
measure of clinical effectiveness in health economic eval-
uations (21).
4.6. Incremental Cost-Effectiveness Ratio
A ﬁnal key concept of economic evaluation is that the
value of an intervention or a program must be considered
in incremental terms compared with the relevant alter-
natives. Cost-effectiveness analysis applies this principle by
comparing the intervention or program of interest with the
best available alternative, much like when a clinical trial
compares a new drug with an active control rather than
with a placebo. The incremental cost-effectiveness ratio
(ICER), which is used to compare a new intervention or
program with its alternative (alt.), is expressed symbolically
as follows:
ICER ¼ ðCnew  Calt:Þ
QALYnew QALYalt:

where C indicates the net cost of the intervention/program
and QALY indicates the quality-adjusted life-years that
result from that intervention/program.
4.7. Use of Cost-Effectiveness Analysis in
Healthcare Decision Making
It is ultimately a matter of judgment whether a medical
program (i.e., an intervention or strategy) produces sufﬁ-
cient improvement in medical outcomes to justify its added
costs. Consequently, no single level of the ICER indicates
that a program is acceptable or worthwhile. In the United
States, the annual cost of dialysis for end-stage renal dis-
ease provided an early benchmark for the assessment of
cost-effectiveness because, although dialysis was costly, the
U.S. Congress mandated that it should be paid for as
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torical precedent is the origin of the oft-cited $50,000 per
QALY benchmark for an acceptable cost-effectiveness
ratio (22). Many would argue that this number is out of date
because the cost of renal dialysis is now higher (23), but
programs below (i.e., more favorable than) this benchmark
continue to be generally accepted in the United States.
The World Health Organization (WHO) has suggested
a rough benchmark of 3 times the GDP per capita as an
upper threshold for an acceptable level of cost-effectiveness
in a given country (24). In 2011, the GDP per capita in the
United States was approximately $48,000, which implies
an upper cost-effectiveness threshold near $150,000 per
QALY. Programs with cost-effectiveness ratios above
this range would generally be considered economically
unattractive, whereas programs with cost-effectiveness ratios
below 1 GDP per capita would generally be considered
affordable and cost-effective ($50,000 per QALY in an
economy with a per capita GDP of the United States).
Cost-effectiveness assessment involves uncertainty. The
cost-effectiveness acceptability curve is a commonly used
graphical way of representing this uncertainty. It reports
the probability that a program under consideration would
be cost-effective over the range of critical willingness-to-
pay thresholds (25). The uncertainty of cost-effectiveness
ﬁndings arises from a number of sources, including
variation in costs, statistical uncertainty in many outcome
parameters, and model variability.
The cost-effectiveness ratio of a medical program (inter-
vention or strategy) is not the only consideration in making
health care decisions. Other considerations, such as equity
and available funds, may override efﬁciency issues reﬂected
in cost-effectiveness estimates. For instance, policy makers
may wish to consider the distributional effects of a program
(i.e., how it affects different segments of the population), or
they may be willing to pay more for the only effective
treatment for a rare disease. Consequently, economic eval-
uations are important to consider when setting healthcare
policy, but they should not be the only factor in decision
making on the allocation of healthcare resources.
Finally, the total budgetary impact of a medical program
also needs to be considered, as it may not be possible to
pay for all healthcare programs that have favorable cost-
effectiveness ratios. For instance, the total cost of imple-
menting a new program may be unaffordable if there are
many affected individuals or the cost of treating each indi-
vidual is very high. This is particularly an issue for inter-
ventions that affect large segments of the population such as
management of hypertension, hyperlipidemia, diabetes
mellitus, heart failure, and other common conditions.
4.8. Challenges in Conducting and
Evaluating Economic Analysis
A number of different guidelines describe cost-
effectiveness methods but are largely consistent in their
recommendations (26).Systematic reviews have considered the strength of evi-
dence of economic evaluations, paying special attention to
methodological differences. Different criteria have been
developed to evaluate the quality of cost-effectiveness
studies (27). One of the earliest, most comprehensive, and
most frequently cited set of criteria was developed for the
British Medical Journal (20,27) (Table 1).
Attempts to deﬁne criteria for quality of economic
analysis and to standardize methodology have been only
partially effective. Several reviews have found that the
quality of cost-effectiveness studies is uneven (27–32).
Economic analysis is intrinsically more complex than
analysis of clinical trials or observational data due to the
need for extrapolative modeling in the absence of empirical
data on all needed points.
There are potential limitations in comparing cost per
QALY gained across studies (33,34). There can be sig-
niﬁcant heterogeneity in study design (e.g., trial analyses
versus modeling), costing methods, discounting, measures
of effectiveness, mechanisms for quality adjustment, and
time horizons (21,33–38). It is recommended that the
quality of each economic study considered be assessed
using a standard, validated tool. The Quality of Health
Economic Studies (QHES) instrument (Table 1) (33) is
one available tool to assess the quality of economic studies.
We recommend that writing committees initially consider
using the QHES tool or an alternative widely used and
validated tool and that the tool selected for use be
explicitly stated in the Methods section of each guideline.
Another limitation in determining the cost-effectiveness
of a treatment or procedure for an individual patient is
that cost and effectiveness may differ across patient sub-
groups, yet data may be inadequate to estimate cost and
effectiveness in these subgroups. A treatment applied to a
high-risk patient will generally provide more value than the
same treatment applied to a low-risk patient, because the
absolute beneﬁt of treatment is greater in the high-risk
patient even when the cost of treatment is the same. As
with determining the effectiveness of treatment for an
individual patient, clinical judgment often is required to
select care that is of high value (and cost-effective). Cost-
effective clinical care therefore involves careful selection of
diagnostic tests and medical therapies for patients, which
is in line with the purpose of guidelines. The reader is
referred to prior reviews for speciﬁc examples of cost-
effectiveness analysis applied to cardiovascular conditions
(39-41). Given these considerations, value assessments
should clearly specify in which populations and countries/
healthcare systems the cost-effectiveness of treatment has
been determined and hence would apply. For the ACC/
AHA guidelines, it generally may be assumed that a U.S.
perspective is given precedence, although consideration of
relevant international experience also is to be encouraged.
In summary, cost-effectiveness analyses alone may not
fully convey the total cost burden to society of a diagnostic
test or therapy, which is inﬂuenced by the cost of the test or
Table 1. Quality of Health Economic Studies Instrument
Modiﬁed with permission Ofman, Joshua J., et al. “Examining the value and quality of health economic analyses: implications of utilizing the QHES.” Journal of Managed Care Pharmacy 9.1
(2003):53–61 (33).
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or therapy is indicated, and the degree to which guideline
recommendations are followed in practice (35,37). Despite
these limitations, cost-effectiveness studies are increasing
in number and quality. More than 1,400 original cost-
effectiveness studies had been published by 2006 (42),
and the quality of studies has increased (43).
5. Considerations for
Cost-Effectiveness/Value Assessment
5.1. Value Assessment Proposal for
Guidelines and Performance Measures
ACC/AHA clinical practice guideline writing committees
create recommendations by using a hierarchical grading
system to classify information obtained from randomized
clinical trials, nonrandomized studies, expert panel con-
sensus, and case studies. This system synthesizes the data
to establish the beneﬁt of diagnostic approaches and treat-
ments compared with risk (COR, ranging from the highest[I] to the lowest [III]) and integrates the precision and,
implicitly, the quality of the underlying evidence (LOE,
from the best [A] to the poorest [C]) (2). In comparing
risks and beneﬁts, the writing committees ultimately
develop a qualitative determination as to whether the
beneﬁts outweigh the risks. In general, this assessment is
based on the number and types of supportive studies
and their statistical signiﬁcance rather than the absolute
magnitude of the beneﬁt or the value provided (cost-
effectiveness) (2). This approach provides a higher class
of recommendations to those diagnostic tests and therapies
where statistically signiﬁcant and clinically relevant
differences are replicated in several randomized clinical
trials, irrespective of value (2).
This document’s writing committee recommends
enhancing the ACC/AHA system for guideline develop-
ment to include an assessment of value when data are
available and reliable. Although other terms, including
cost-effectiveness, cost utility, resource utilization, and
efﬁciency were considered, the writing group favored the
primary use of the term “value.” The writing committee
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guideline accompanying individual recommendations,
particularly for Class I and IIa recommendations, when
supporting data are available. Speciﬁcally, the writing
committee proposes that the literature search for each
recommendation be expanded from the current search for
outcomes evidence to include a search for health economic
data, including cost-effectiveness/resource use/value anal-
yses. Further, the writing committee proposes that when-
ever reports are available and graded as being of good
quality (e.g., by using QHES [Table 1]), a value
assessment for that recommendation should be included
in the guidelines. However, the writing committee also
believes that explicitly deﬁning a level of value to directly
change the class of recommendation or level of (clinical)
evidence (i.e., COR/LOE) is problematic and could vary,
depending on the particular disease state, the particular
intervention, the particular outcome, and the particular
health care delivery system. By providing a meaningful
framework for converting the available data on magnitude
of beneﬁt and cost-effectiveness into a level of value to
accompany the COR, our cost methodology report will
help establish a standard for clinical guidelines to convey
the level of value (i.e., high, intermediate, or low)
provided by diagnostic tests and therapies.
Under this suggested revision, guideline recom-
mendations would consist of the COR, level or quality of
evidence, and level of value (Table 2). The inclusion of this
additional value assessment provides a framework in which
the rational use of diagnostic tests and therapies can be
communicated based on available evidence, supporting
more efﬁcient use of resources.
To illustrate, under current guideline development
conventions, a therapy for which 2 randomized controlled
trials demonstrated a statistically signiﬁcant reduction in
all-cause mortality with beneﬁts exceeding risks would be
given a Class I recommendation with an “A” level of evi-
dence, irrespective of cost, cost-effectiveness, or value.
Under the proposed approach, if the therapy provided aTable 2. Proposed Integration of Level of Value Into
Clinical Guideline Recommendations*
Level of Value
High value: better outcomes at lower cost or ICER <$50,000 per QALY gained
Intermediate value: $50,000 to <$150,000 per QALY gained
Low value: $150,000 per QALY gained
Uncertain value: value examined but data are insufﬁcient to draw a conclusion
because of no studies, low-quality studies, conﬂicting studies, or prior
studies that are no longer relevant
Not assessed: value not assessed by the writing committee
Proposed abbreviations for each value recommendation:
Level of Value: H to indicate high value I, intermediate value; L, low value; U, uncertain value; and
NA, value not assessed
*Figures used in this table are based on U.S. GDP data from 2012 and were obtained from
WHO-CHOICE Cost-Effectiveness Thresholds (24).
GDP indicates gross domestic product; ICER, incremental cost-effectiveness ratio; QALY,
quality-adjusted life-year; and WHO-CHOICE, World Health Organization Choosing Interventions
that are Cost Effective.large and enduring reduction in mortality, was of modest
cost, or both, and published studies demonstrated that
the cost per QALYs gained was <$50,000 or the therapy
was economically dominant (produced health gains and
cost savings), the therapy would be given a Class I rec-
ommendation, an “A” level of evidence, and an “H” (high)
level of value. Conversely, if the cost-effectiveness of this
therapy was less favorable and studies demonstrated the
cost per QALYs gained was >$150,000, it would be given
an “L” (low) level of value recommendation. In exceptional
cases, a resource-intensive therapy that may provide the
only effective/lifesaving treatment available for a rare or
advanced condition may be assessed as being of “low value”
but considered appropriate by society. In these cases, the
designation “high-resource utilization” may be preferred,
potentially adding a parenthetical (e.g., effective/lifesaving)
rather than applying the term “low value.”
As noted above, the present writing committee de-
ﬁned high, intermediate, and low value according to
the WHO-CHOICE (Choosing Interventions that are
Cost-Effective) project http://www.who.int/choice/cost-
effectiveness/en/(http://www.who.int/choice/costs/CER_
thresholds/en/), which provides a framework for cost-
effectiveness thresholds that can be applied globally to a
wide range of health interventions (21,36,38). The 3
categories of cost-effectiveness are highly cost-effective
(less than GDP per capita), cost-effective (between 1 and
3 times GDP per capita), and not cost-effective (>3 times
GDP per capita) (24). In adapting these WHO-CHOICE
recommended thresholds, the values shown in Table 2
were selected by the writing group as initial threshold
recommendations. In the future, these thresholds may
need modiﬁcation as additional information becomes
available or different national consensus standards for
value-based thresholds are developed.
5.2. Recommendations for Implementation of
Value Assessment
This document’s writing committee recognizes that inte-
grating studies of cost-effectiveness and healthcare value
into the guideline development process may be potentially
resource intensive. Guideline writing committees or com-
missioned systematic review committees need to be explicit
about the approach used. It is not necessarily the role of
guideline writing committees to conduct their own formal
cost-effectiveness analyses, but having a well-deﬁned and
objective approach to systematically evaluating the avail-
able published studies on cost-effectiveness and grading
their quality is important. For example, cost-effectiveness
evaluations may be delegated to an appropriately trained
and experienced evidence review committee. An explicit
delineation of the formal process for evaluating existing
cost-effectiveness evidence should be developed by soci-
eties, including the ACC and AHA. This process should
take steps to minimize potential conﬂicts of interest among
members of writing committees or groups performing a
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cost-effectiveness studies. For reliability and reproduci-
bility, the quality of cost-effectiveness studies should be
evaluated using consistent and objective methods. At a
minimum, the present writing committee proposes that a
health economist be available to every guideline writing
committee or related evidence review committee; the
health economist should be involved in the selection and
grading of resource-related studies. A comprehensive lit-
erature review across all relevant guidelines statements
should be made, and, as noted above, a standardized
approach to study evaluation (e.g., initially the QHES
instrument) should be used.
The systematic reviews of cost-effectiveness analyses
should preferentially use the societal perspective in deﬁning
cost-effectiveness. The societal-level approach for value
recommendations, however, contrasts with the patient-
level approach for diagnostic and treatment recom-
mendations of the ACC/AHA guidelines. To emphasize
this contrast in using value recommendations by the
practitioner, we propose separating value recommendations
from the diagnostic/treatment recommendations (e.g., in
separate tables and text).
In addition, for the ACC/AHA guidelines, value rec-
ommendations generally should be limited to assessments
of cost-effectiveness information generated in or relevant
to the United States and/or North America (to avoid
confusion with health economic analyses generated in
other healthcare settings). Special attention should be
given to ensuring that the value assessment is based on the
entire clinical population included in guideline recom-
mendations. Caution is also suggested with the recognition
that guidelines often assume that treatment beneﬁts apply
uniformly across the entire population studied. However,
both beneﬁt and cost often differ among patient pop-
ulations, and thus value is also likely to vary in important
ways across subgroups. It is hoped that these proposed
revisions to the guideline development process, that is,
conveying information on those therapies that have the
strongest evidence and provide the greatest value, may
allow for better prioritization in healthcare resource uti-
lization and may optimize efﬁciency in achieving superior
outcomes.
How might clinicians use this information in making
treatment decisions for individual patients in their practice?
Given the state of the science, gaps in the value evidence
base, and the frequency with which it may change, the
ACC and AHA will not yet be prescriptive regarding how
best to incorporate value when using guideline recom-
mendations at the point of care. Rather, where available,
value should be recognized and broadly considered when
integrating the risk-beneﬁt ratio, LOE, and quality of
evidence of a speciﬁc recommendation in a speciﬁc patient.
At present, each clinician should start by considering rel-
evant, highly graded COR/LOE recommendations (i.e.,
I-IIa/A-B). Second, the clinician should then review theLOV assessment. A high LOV adds a strong endorsement
to proceed with the treatment or test. In the case of
alternative recommendations, a higher LOV evaluation of
a treatment/test may suggest its selection over a lower
LOV alternative. In the exceptional case of a treatment
with a high COR/LOE but low LOV (e.g., possibly, use
of a left ventricular assist device as a bridge to transplant)
that is deemed uniquely effective/lifesaving, the desig-
nation “high resource utilization” rather than “low value”
may be applied and may support appropriate and selective
use. For lower COR recommendations (e.g., IIb), a low
LOV may reinforce a decision to forego the treatment/test.
Clinical judgment and individual circumstances may be
especially important for intermediate-value treatments/
tests and discrepancies between COR/LOE and LOV.
The use of LOV as a tiebreaker in uncertain clinical sce-
narios rather than prescriptive requirements should strike
the correct balance in informing and enhancing clinical
practice. As the science and methodology of value assess-
ment evolve, so too will the ACC/AHA grading system.
Finally, how will patients and the public respond to this
initiative? The potential for its being viewed negatively, as
limiting quality of care and therapeutic options, is real. On
the contrary, and fortunately, discussions among groups of
informed lay public and patient representatives have
endorsed the need for thorough, objective assessments of
value in medical care and concerns about inappropriate
resource utilization in contrast to simple cost comparisons
(44). Moreover, the ACC and AHA remain committed
to engaging patient representatives (45) who now serve
on the Task Force on Practice Guidelines and guideline
writing committees in the discussion and dissemination
of these concepts.6. Special Considerations for
Performance Measures
Performance measures are an integral part of the cycle of
quality of care improvement. Once the evidence from
randomized clinical trials and observational studies is
summarized into clinical practice guidelines, the ACC/
AHA Task Force on Performance Measures evaluates
those recommendations with the strongest evidence to
consider which should become a clinical performance
measure. If guideline recommendations tell clinicians what
they should consider, performance measures tell them
which of these recommendations they must follow to
optimize patient outcomes. Performance measures there-
fore are useful as direct measures of the quality of care
given by a provider or provider group. To be reﬂective of
provider quality, performance measures and deﬁnitions also
must possess several key attributes, including being clearly
and precisely deﬁned and being able to be reliably, repro-
ducibly, and practically assessed in real-world clini-
cal practice. Performance measures also should be
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viders and health systems to improve care.
Although direct consideration of the cost or cost-
effectiveness of a procedure or therapy has not been tra-
ditionally one of the key attributes considered when
selecting a performance measure, economic issues have
been implicitly considered. In a recent update to the
methodology used to create performance measures, the
Task Force on Performance Measures summarized its
views on the topic as follows:
The writing committee believes that it is important to consider
both the cost-effectiveness and total cost burden of potential
performance measures before selection. Although these may
change over time, explicitly quantifying the cost-effectiveness
of treatments at the time that performance measures are
created is aligned with the Institute of Medicine (IOM) goal
for a more efﬁcient healthcare system and will minimize the
likelihood that unintended economic consequences for society
and hospitals emerge from adopting a measure. (2)
In this same document, the Task Force on Performance
Measures stressed the need for unbiased and high-quality
cost-effectiveness analyses for given therapies, acknowl-
edging the general challenges in calculating ICERs (e.g.,
the appropriate comparator group, time horizon, or per-
spective) as noted above. This task force also recognized
the difﬁculty in deﬁning an empirical cut-point for the
cost-effectiveness ratio that would preclude selecting a
given intervention for incorporation into a performance
measure.
The framework described above for the explicit consid-
eration of cost in guideline recommendations has important
implications for performance measurements. Previously,
any Class I guideline recommendation could be considered
as a potential performance measure, provided that the other
criteria, such as validity, reliability, and existing gaps in care
and feasibility, could be demonstrated. The introduction of
value assessments as part of guidelines recommendations
will inform developers of performance measures in priori-
tizing Class I recommendations for consideration. Class I
recommendations labeled a poor value would not be con-
sidered for performance measures. Class I recom-
mendations of uncertain value or with no available value
data would have lower priority than those of high value.
7. Future Directions
This report describes how the ACC and AHA can begin
to address the cost/value of care when making guideline
recommendations or developing performance measures.
However, several barriers will need to be overcome before
a value can be fully incorporated into guidelines or per-
formance measures documents.
The primary barrier is the lack of high-quality data on
cost and value (cost-effectiveness) of interventions or
procedures used in practice. Fortunately, a growingnumber of clinical trials now include an economic com-
ponent that can serve to estimate the cost of care for a new
treatment or diagnostic test during the trial period. Cost of
care and survival rates that differed at completion of the
trial will likely differ at subsequent times. Thus modeling is
often required to determine the beneﬁt and cost of an
intervention over the patient’s lifetime. Such models are
often limited owing to imprecise estimates of treatment
effects, competing risks, and future costs of care. As such
trials and modeling data become available, they can be
added to future updates of guidelines and performance
measures. For now, it expected that a minority of care
practices in cardiology will have adequate economic data to
inform a recommendation on value, but it is anticipated
that over time this proportion will increase. The appro-
priate method for evaluating studies of cost-effectiveness is
unclear. An additional future initiative should include a
review of all available grading tools, and if these are lack-
ing, potentially development and validation of a custom-
ized tool to best serve the ACC/AHA guidelines for
grading cost-effectiveness/resource utilization studies.
The optimal cost-effectiveness threshold for determin-
ing value also is not entirely clear. As discussed above, the
WHO has recommended that this threshold be tied to
the wealth of the country as deﬁned by GDP per capita.
Given the uncertainty in the optimal threshold, we rec-
ommend the use of 2 thresholds initially: a lower threshold
to identify an upper boundary for good value and a high
threshold to identify poor value, with the remaining values
considered intermediate.
The cost of care and hence the value of a given inter-
vention often changes more rapidly than evidence of
beneﬁt. For example, if a medication becomes generic
1 year after a guideline is written, the value determination
would no longer be accurate and may have changed from
poor (low) to good (high). The ability to rapidly reassess
value and subsequently update guideline recommendations
will be important to accommodate changes in value over
time. Further, care originally assessed as high value can
become low value, such as when care is extended beyond a
speciﬁc patient group in which efﬁcacy has been proven.
Another area of uncertainty is the incorporation of
quality of life into value. Clearly, a treatment that improves
quality of life at a reasonable cost has some value even if it
does not improve life expectancy. Combining quality and
length of life provides a more accurate estimate of the
beneﬁt of any intervention or program. Cost-effectiveness
analysis makes the assumption that all QALYs are equiv-
alent, but healthcare decision makers may favor inter-
ventions that beneﬁt disadvantaged groups, including those
with little life expectancy (e.g., the elderly) and those with a
baseline lower quality of life (e.g., those with certain birth
defects). Decision makers must consider both equity and
optimization of population health.
Incorporation of value assessments may have an imme-
diate impact, as low-value care generally should not be the
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2317basis of performance measures unless there are exceptional
considerations regarding equity or other speciﬁc justiﬁ-
cations. Future performance measure documents may
incorporate the cost of implementing the measures in
addition to the value of the care. By determining the value
(cost-effectiveness) of an intervention or program, it can
then be determined if and how much additional funds
should be spent implementing performance measures (or
other quality improvement activities) such that the com-
bined value of treatment and implementation still repre-
sents high value. In conclusion, this document’s writing
committee acknowledges that it is time to accept the
challenge inherent in determining how best to integrate
quality care, quality of life, and improved outcomes with
value to patients and society by including value information
in guideline and performance measure recommendations.
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2319Appendix 1. ACC/AHA Classiﬁcation of Recommendations and Level of EvidenceA recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials.
Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial infarction, history of
heart failure, and prior aspirin use.
yFor comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments
or strategies being evaluated.
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